Lowest-Rated StocksLowest-RatedNASDAQ:CBAY CymaBay Therapeutics (CBAY) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free CBAY Stock Alerts $32.48 0.00 (0.00%) (As of 04/1/2024) Add Compare Share Share Today's Range$32.48▼$32.4850-Day Range$32.17▼$32.4852-Week Range$7.26▼$32.50Volume73 shsAverage Volume4.11 million shsMarket Capitalization$3.73 billionP/E RatioN/ADividend YieldN/APrice Target$28.65 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get CymaBay Therapeutics alerts: Email Address CymaBay Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.08 Rating ScoreUpside/Downside11.8% Downside$28.65 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$191,820 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.38) to ($1.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.00 out of 5 starsMedical Sector794th out of 915 stocksPharmaceutical Preparations Industry372nd out of 424 stocks 2.0 Analyst's Opinion Consensus RatingCymaBay Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 1 buy rating, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageCymaBay Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CBAY. Previous Next 0.0 Dividend Strength Dividend YieldCymaBay Therapeutics does not currently pay a dividend.Dividend GrowthCymaBay Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCymaBay Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CymaBay Therapeutics is -0.88. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for CymaBay Therapeutics this week, compared to 4 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CymaBay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $191,820.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of CymaBay Therapeutics is held by insiders.Percentage Held by Institutions95.03% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CymaBay Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CymaBay Therapeutics is -33.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCymaBay Therapeutics has a P/B Ratio of 12.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About CymaBay Therapeutics Stock (NASDAQ:CBAY)CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.Read More CBAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CBAY Stock News HeadlinesApril 27, 2024 | americanbankingnews.comCymaBay Therapeutics (NASDAQ:CBAY) Coverage Initiated at StockNews.comApril 19, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on CymaBay Therapeutics (NASDAQ:CBAY)April 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 22, 2024 | za.investing.comGilead reduces 2024 earnings guidance after completing CymaBay takeoverMarch 22, 2024 | markets.businessinsider.comGilead Sciences Completes Acquisition Of CymaBay TherapeuticsMarch 22, 2024 | businesswire.comGilead Sciences Announces Completion of Acquisition of CymaBayMarch 16, 2024 | finance.yahoo.comCBAY Jul 2024 34.000 callMarch 16, 2024 | finance.yahoo.comCBAY Apr 2024 31.000 putApril 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 16, 2024 | finance.yahoo.comCBAY Oct 2024 33.000 callMarch 16, 2024 | finance.yahoo.comCBAY Oct 2024 29.000 putMarch 11, 2024 | finance.yahoo.comInvesting in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gainMarch 4, 2024 | globenewswire.comCymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary CholangitisFebruary 29, 2024 | markets.businessinsider.comMaintaining Hold on CymaBay Amid Gilead Acquisition Deal ClosureFebruary 29, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of CymaBay Therapeutics, Inc. (CBAY)February 28, 2024 | marketwatch.comCymaBay Therapeutics 4Q Loss/Shr 35c >CBAYFebruary 28, 2024 | globenewswire.comCymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate UpdateFebruary 24, 2024 | msn.comCymaBay Therapeutics (CBAY) Price Target Increased by 12.84% to 31.37February 21, 2024 | finance.yahoo.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 21, 2024 | prnewswire.comThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary CholangitisFebruary 20, 2024 | msn.comLeerink Partners Downgrades CymaBay Therapeutics (CBAY)February 20, 2024 | globenewswire.comCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 16, 2024 | businesswire.comCYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAYFebruary 15, 2024 | finance.yahoo.comCBAY Jan 2026 37.000 callFebruary 14, 2024 | finance.yahoo.comCBAY Feb 2024 33.000 callFebruary 14, 2024 | finance.yahoo.comCBAY Jan 2025 8.000 putFebruary 13, 2024 | seekingalpha.comCymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver FranchiseSee More Headlines Receive CBAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CBAY CUSIPN/A CIK1042074 Webwww.cymabay.com Phone(510) 293-8800Fax510-293-9090Employees101Year FoundedN/APrice Target and Rating Average Stock Price Target$28.65 High Stock Price Target$32.50 Low Stock Price Target$15.00 Potential Upside/Downside-11.8%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-105,370,000.00 Net MarginsN/A Pretax Margin-339.11% Return on Equity-50.72% Return on Assets-31.04% Debt Debt-to-Equity RatioN/A Current Ratio10.96 Quick Ratio10.96 Sales & Book Value Annual Sales$31.07 million Price / Sales119.92 Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book12.59Miscellaneous Outstanding Shares114,724,000Free Float106,693,000Market Cap$3.73 billion OptionableOptionable Beta0.32 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Sujal A. Shah (Age 51)President, CEO & Director Comp: $1.04MDr. Charles A. McWherter Ph.D. (Age 69)President of Research & Development and Chief Scientific Officer Comp: $700.65kMr. Paul T. Quinlan (Age 61)General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $629.72kMr. Harish Shantharam C.F.A. (Age 42)CFO, Principal Accounting & Financial Officer Mr. Ken BoehmSenior Vice President of Human ResourcesMr. Patrick J. O'Mara (Age 63)Senior Vice President of Business Development Dr. Robert L. Martin (Age 62)Senior Vice President of Manufacturing & Nonclinical Development Ms. Klara A. Dickinson-Eason (Age 56)Chief Regulatory & Quality Assurance Officer Comp: $441.84kMs. Becki Filice (Age 63)Senior Vice President of Portfolio & Product Leadership Mr. Ben KozubHead of CommercialMore ExecutivesKey CompetitorsUltragenyx PharmaceuticalNASDAQ:RAREInsmedNASDAQ:INSMPrestige Consumer HealthcareNYSE:PBHAxsome TherapeuticsNASDAQ:AXSMAlkermesNASDAQ:ALKSView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 7,756 shares on 3/22/2024Ownership: 0.007%Vanguard Group Inc.Bought 558,562 shares on 3/11/2024Ownership: 5.497%Wellington Management Group LLPBought 202,782 shares on 3/5/2024Ownership: 0.177%Tucker Asset Management LLCBought 3,749 shares on 3/4/2024Ownership: 0.003%Perceptive Advisors LLCSold 18,791 shares on 2/26/2024Ownership: 3.549%View All Insider TransactionsView All Institutional Transactions CBAY Stock Analysis - Frequently Asked Questions Should I buy or sell CymaBay Therapeutics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CBAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBAY, but not buy additional shares or sell existing shares. View CBAY analyst ratings or view top-rated stocks. What is CymaBay Therapeutics' stock price target for 2024? 12 brokers have issued 12-month price objectives for CymaBay Therapeutics' stock. Their CBAY share price targets range from $15.00 to $32.50. On average, they anticipate the company's stock price to reach $28.65 in the next year. This suggests that the stock has a possible downside of 11.8%. View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts. How have CBAY shares performed in 2024? CymaBay Therapeutics' stock was trading at $23.62 at the start of the year. Since then, CBAY stock has increased by 37.5% and is now trading at $32.48. View the best growth stocks for 2024 here. When is CymaBay Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CBAY earnings forecast. How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics, Inc. (NASDAQ:CBAY) issued its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company earned $0.06 million during the quarter, compared to analyst estimates of $0.42 million. What ETFs hold CymaBay Therapeutics' stock? ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB) and AltShares Event-Driven ET (EVNT).AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC). What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX). How do I buy shares of CymaBay Therapeutics? Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CBAY) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingUrgent Nvidia WarningAltimetryHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.